Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Use of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder.

Bartsch G Jr, Mitra AP, Mitra SA, Almal AA, Steven KE, Skinner DG, Fry DW, Lenehan PF, Worzel WP, Cote RJ.

J Urol. 2016 Feb;195(2):493-8. doi: 10.1016/j.juro.2015.09.090. Epub 2015 Oct 13.

PMID:
26459038
2.

Generation and external validation of a tumor-derived 5-gene prognostic signature for recurrence of lymph node-negative, invasive colorectal carcinoma.

Lenehan PF, Boardman LA, Riegert-Johnson D, De Petris G, Fry DW, Ohrnberger J, Heyman ER, Gerard B, Almal AA, Worzel WP.

Cancer. 2012 Nov 1;118(21):5234-44. doi: 10.1002/cncr.27628. Epub 2012 May 17.

3.

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor.

Gonzales AJ, Hook KE, Althaus IW, Ellis PA, Trachet E, Delaney AM, Harvey PJ, Ellis TA, Amato DM, Nelson JM, Fry DW, Zhu T, Loi CM, Fakhoury SA, Schlosser KM, Sexton KE, Winters RT, Reed JE, Bridges AJ, Lettiere DJ, Baker DA, Yang J, Lee HT, Tecle H, Vincent PW.

Mol Cancer Ther. 2008 Jul;7(7):1880-9. doi: 10.1158/1535-7163.MCT-07-2232. Epub 2008 Jul 7.

4.

The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer.

Mitra AP, Almal AA, George B, Fry DW, Lenehan PF, Pagliarulo V, Cote RJ, Datar RH, Worzel WP.

BMC Cancer. 2006 Jun 16;6:159.

5.

Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells.

Saab R, Bills JL, Miceli AP, Anderson CM, Khoury JD, Fry DW, Navid F, Houghton PJ, Skapek SX.

Mol Cancer Ther. 2006 May;5(5):1299-308.

6.

Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.

Klutchko SR, Zhou H, Winters RT, Tran TP, Bridges AJ, Althaus IW, Amato DM, Elliott WL, Ellis PA, Meade MA, Roberts BJ, Fry DW, Gonzales AJ, Harvey PJ, Nelson JM, Sherwood V, Han HK, Pace G, Smaill JB, Denny WA, Showalter HD.

J Med Chem. 2006 Feb 23;49(4):1475-85.

PMID:
16480284
7.

2-Aminoquinazoline inhibitors of cyclin-dependent kinases.

Bathini Y, Singh I, Harvey PJ, Keller PR, Singh R, Micetich RG, Fry DW, Dobrusin EM, Toogood PL.

Bioorg Med Chem Lett. 2005 Sep 1;15(17):3881-5.

PMID:
15993068
8.

Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor.

Christensen JG, Vincent PW, Klohs WD, Fry DW, Leopold WR, Elliott WL.

Mol Cancer Ther. 2005 Jun;4(6):938-47.

9.

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, Keller PR, McNamara DJ, Sherry D, Zhu T, Brodfuehrer J, Choi C, Barvian MR, Fry DW.

J Med Chem. 2005 Apr 7;48(7):2388-406.

PMID:
15801831
10.

Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.

VanderWel SN, Harvey PJ, McNamara DJ, Repine JT, Keller PR, Quin J 3rd, Booth RJ, Elliott WL, Dobrusin EM, Fry DW, Toogood PL.

J Med Chem. 2005 Apr 7;48(7):2371-87.

PMID:
15801830
11.
12.

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL.

Mol Cancer Ther. 2004 Nov;3(11):1427-38.

13.

CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer.

Allen LF, Eiseman IA, Fry DW, Lenehan PF.

Semin Oncol. 2003 Oct;30(5 Suppl 16):65-78. Review.

PMID:
14613028
14.

Mechanism of action of erbB tyrosine kinase inhibitors.

Fry DW.

Exp Cell Res. 2003 Mar 10;284(1):131-9. Review.

PMID:
12648472
15.

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer.

Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW.

Semin Oncol. 2002 Jun;29(3 Suppl 11):11-21. Review.

PMID:
12138393
16.

Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy.

Citri A, Alroy I, Lavi S, Rubin C, Xu W, Grammatikakis N, Patterson C, Neckers L, Fry DW, Yarden Y.

EMBO J. 2002 May 15;21(10):2407-17.

17.

Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.

Bishop PC, Myers T, Robey R, Fry DW, Liu ET, Blagosklonny MV, Bates SE.

Oncogene. 2002 Jan 3;21(1):119-27.

18.

CI-1033, a pan-erbB tyrosine kinase inhibitor.

Slichenmyer WJ, Elliott WL, Fry DW.

Semin Oncol. 2001 Oct;28(5 Suppl 16):80-5. Review.

PMID:
11706399
19.

Anticancer therapy targeting the erbB family of receptor tyrosine kinases.

Slichenmyer WJ, Fry DW.

Semin Oncol. 2001 Oct;28(5 Suppl 16):67-79. Review.

PMID:
11706398
20.

Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.

Stoll SW, Kansra S, Peshick S, Fry DW, Leopold WR, Wiesen JF, Sibilia M, Zhang T, Werb Z, Derynck R, Wagner EF, Elder JT.

Neoplasia. 2001 Jul-Aug;3(4):339-50.

21.

Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.

Smaill JB, Showalter HD, Zhou H, Bridges AJ, McNamara DJ, Fry DW, Nelson JM, Sherwood V, Vincent PW, Roberts BJ, Elliott WL, Denny WA.

J Med Chem. 2001 Feb 1;44(3):429-40.

PMID:
11462982
22.

Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.

Fry DW, Bedford DC, Harvey PH, Fritsch A, Keller PR, Wu Z, Dobrusin E, Leopold WR, Fattaey A, Garrett MD.

J Biol Chem. 2001 May 18;276(20):16617-23. Epub 2001 Feb 6.

23.
24.

Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in ApcMin mice but induces duodenal injury.

Ritland SR, Gendler SJ, Burgart LJ, Fry DW, Nelson JM, Bridges AJ, Andress L, Karnes WE Jr.

Cancer Res. 2000 Sep 1;60(17):4678-81.

26.

Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts.

Vincent PW, Bridges AJ, Dykes DJ, Fry DW, Leopold WR, Patmore SJ, Roberts BJ, Rose S, Sherwood V, Zhou H, Elliott WL.

Cancer Chemother Pharmacol. 2000;45(3):231-8.

PMID:
10663641
30.

Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors.

Sun Y, Fry DW, Vincent P, Nelson JM, Elliott W, Leopold WR.

Anticancer Res. 1999 Mar-Apr;19(2A):919-24.

PMID:
10368634
31.

Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.

Smaill JB, Palmer BD, Rewcastle GW, Denny WA, McNamara DJ, Dobrusin EM, Bridges AJ, Zhou H, Showalter HD, Winters RT, Leopold WR, Fry DW, Nelson JM, Slintak V, Elliot WL, Roberts BJ, Vincent PW, Patmore SJ.

J Med Chem. 1999 May 20;42(10):1803-15.

PMID:
10346932
32.
33.

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.

Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S, Dobrusin EM.

Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):12022-7.

34.

Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathway.

Cunnick JM, Dorsey JF, Standley T, Turkson J, Kraker AJ, Fry DW, Jove R, Wu J.

J Biol Chem. 1998 Jun 5;273(23):14468-75.

36.
37.

Inhibitors of tyrosine kinase.

Klohs WD, Fry DW, Kraker AJ.

Curr Opin Oncol. 1997 Nov;9(6):562-8. Review.

PMID:
9370078
38.

Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor.

Fry DW, Nelson JM, Slintak V, Keller PR, Rewcastle GW, Denny WA, Zhou H, Bridges AJ.

Biochem Pharmacol. 1997 Oct 15;54(8):877-87.

PMID:
9354588
39.

Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.

Hamby JM, Connolly CJ, Schroeder MC, Winters RT, Showalter HD, Panek RL, Major TC, Olsewski B, Ryan MJ, Dahring T, Lu GH, Keiser J, Amar A, Shen C, Kraker AJ, Slintak V, Nelson JM, Fry DW, Bradford L, Hallak H, Doherty AM.

J Med Chem. 1997 Jul 18;40(15):2296-303.

PMID:
9240345
42.
43.
44.

Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.

Showalter HD, Sercel AD, Leja BM, Wolfangel CD, Ambroso LA, Elliott WL, Fry DW, Kraker AJ, Howard CT, Lu GH, Moore CW, Nelson JM, Roberts BJ, Vincent PW, Denny WA, Thompson AM.

J Med Chem. 1997 Feb 14;40(4):413-26.

PMID:
9046331
45.

Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro.

Denny WA, Rewcastle GW, Bridges AJ, Fry DW, Kraker AJ.

Clin Exp Pharmacol Physiol. 1996 May;23(5):424-7.

PMID:
8713682
46.

Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.

Rewcastle GW, Palmer BD, Thompson AM, Bridges AJ, Cody DR, Zhou H, Fry DW, McMichael A, Denny WA.

J Med Chem. 1996 Apr 26;39(9):1823-35.

PMID:
8627606
48.

Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.

Rewcastle GW, Palmer BD, Bridges AJ, Showalter HD, Sun L, Nelson J, McMichael A, Kraker AJ, Fry DW, Denny WA.

J Med Chem. 1996 Feb 16;39(4):918-28.

PMID:
8632415
49.

Expression, purification and characterization of focal adhesion kinase using a baculovirus system.

Withers BE, Keller PR, Fry DW.

Protein Expr Purif. 1996 Feb;7(1):12-8.

PMID:
9172776
50.

Supplemental Content

Support Center